Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMRA-335140 in Major Depressive Episode Associated With Bipolar II Disorder
NCT06429722Phase 2Completed
- Sponsor
- Neumora Therapeutics, Inc.
- Start
- May 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bipolar disorder (BD) comparing NMRA-335140 80 mg QD with Placebo (2 arms). Primary endpoint: Montgomery-Asberg Depression Rating Scale at 6 weeks. Started May 2024; status: completed.
02
Drugs
navacaprant
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT06429722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06429722.